# SCD-Haplo: Phase II Study of HLA-Haploidentical SCT for Aggressive SCD

> **NCT02013375** · PHASE2 · TERMINATED · sponsor: **Damiano Rondelli, MD** · enrollment: 2 (actual)

## Conditions studied

- Sickle Cell Disease

## Interventions

- **PROCEDURE:** Haploidentical Transplant
- **DRUG:** Alemtuzumab
- **RADIATION:** Total Body Irradiation
- **DRUG:** Cyclophosphamide
- **DRUG:** Sirolimus

## Key facts

- **NCT ID:** NCT02013375
- **Lead sponsor:** Damiano Rondelli, MD
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2014-04-10
- **Primary completion:** 2014-05-31
- **Final completion:** 2018-09-07
- **Target enrollment:** 2 (ACTUAL)
- **Last updated:** 2019-08-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02013375

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02013375, "SCD-Haplo: Phase II Study of HLA-Haploidentical SCT for Aggressive SCD". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02013375. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*